This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, L.
Right arrow Articles by Molla, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, L.
Right arrow Articles by Molla, A.

Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 1889-1896, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01004-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759{triangledown}

Liangjun Lu,1* Hongmei Mo,2 Tami J. Pilot-Matias,1 and Akhteruzzaman Molla1

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois,1 Gilead Sciences, Foster City, California2

Received 11 August 2006/ Returned for modification 25 September 2006/ Accepted 12 March 2007

Treatment of hepatitis C virus (HCV) replicon cells with any single specific anti-HCV inhibitor in vitro leads to a rapid selection of resistant mutants. However, the source and the kinetic evolution of these resistant mutants during treatment are poorly understood. In this study we developed allele-specific real-time PCR assays for quantitative detection of the M414T mutant that was selected by a number of benzothiadiazine HCV polymerase inhibitors. Low levels of preexisting M414T mutants were detected in both 1b-con1 (0.22%) and 1b-N (0.18%) subgenomic replicon cell lines, as well as in 6 of 15 HCV RNA isolated from the sera of treatment-naive HCV-infected patients ranging from 0.11 to 0.60%. The proportion of M414T mutants in replicons rapidly increased in a dose-dependent manner upon treatment with benzothiadiazine inhibitor A-782759. After 4 days of treatment, 2.5, 26, or 60% of the replicon population contained M414T mutants with the use of A-782759 at 1x, 10x, or 100x its 50% effective concentration, respectively. In addition, the short 4-day treatment resulted in significant changes in inhibitor susceptibility in the replicon cells. Our results indicated that the resistant mutant preexisted as a minor population in replicon cells and that the mutant was selected within days of treatment with the inhibitor. The findings from this study suggested that early application of combination therapy of an HCV-specific inhibitor with interferon-based regimens or other classes of available inhibitors will be necessary to avoid quick viral rebound or treatment failure.

* Corresponding author. Mailing address: Global Pharmaceutical Research and Development, Abbott Laboratories, GPRD-R4CQ, 200 Abbott Park Rd., Abbott Park, IL 60064. Phone: (847) 935-8314. Fax: (847) 938-3403. E-mail: liangjun.lu{at}abbott.com

{triangledown} Published ahead of print on 19 March 2007.

Antimicrobial Agents and Chemotherapy, June 2007, p. 1889-1896, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01004-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fang, J., Wichroski, M. J., Levine, S. M., Baldick, C. J., Mazzucco, C. E., Walsh, A. W., Kienzle, B. K., Rose, R. E., Pokornowski, K. A., Colonno, R. J., Tenney, D. J. (2009). Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates. Antimicrob. Agents Chemother. 53: 2762-2772 [Abstract] [Full Text]  
  • Pawlotsky, J.-M. (2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology 2: 205-219 [Abstract]  
  • Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., Klumpp, K., Symons, J., Cammack, N., Jiang, W.-R. (2008). Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479. Antimicrob. Agents Chemother. 52: 4356-4369 [Abstract] [Full Text]  
  • Howe, A. Y. M., Cheng, H., Johann, S., Mullen, S., Chunduru, S. K., Young, D. C., Bard, J., Chopra, R., Krishnamurthy, G., Mansour, T., O'Connell, J. (2008). Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796. Antimicrob. Agents Chemother. 52: 3327-3338 [Abstract] [Full Text]  
  • McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., Najera, I. (2008). The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors. Antimicrob. Agents Chemother. 52: 1604-1612 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»